IL33 and cancer: Increased expression of IL‐33 has been associated with immunosuppression, reduced cytotoxicity of CD8+ T cells, and impaired antitumor function.[23] A recent study suggested that IL‐33 can facilitate the fibroblast‐to‐myofibroblast transition through M2 macrophages, thereby promoting cancer progression and metastasis.[24] Notably, the IE subtype exhibited abundant expression of IL‐33, along with an abundance of the aforementioned cell types.